GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Candel Therapeutics Inc (NAS:CADL) » Definitions » 6-1 Month Momentum %

CADL (Candel Therapeutics) 6-1 Month Momentum % : 19.79% (As of Mar. 26, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Candel Therapeutics 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-03-26), Candel Therapeutics's 6-1 Month Momentum % is 19.79%.

The industry rank for Candel Therapeutics's 6-1 Month Momentum % or its related term are showing as below:

CADL's 6-1 Month Momentum % is ranked better than
76.61% of 1479 companies
in the Biotechnology industry
Industry Median: -9.18 vs CADL: 19.79

Competitive Comparison of Candel Therapeutics's 6-1 Month Momentum %

For the Biotechnology subindustry, Candel Therapeutics's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Candel Therapeutics's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Candel Therapeutics's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Candel Therapeutics's 6-1 Month Momentum % falls into.



Candel Therapeutics  (NAS:CADL) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Candel Therapeutics  (NAS:CADL) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Candel Therapeutics 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Candel Therapeutics's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Candel Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Executives
Paul Peter Tak director, officer: President & CEO CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Francesca Barone officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Seshu Tyagarajan officer: See Remarks CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Paul B Manning director 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Estuardo Aguilar-cordova director, officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Nicoletta Loggia director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM MA 02494
Jason Amello officer: Chief Financial Officer 500 KENDALL STREET, CAMBRIDGE MA 01824
Christopher Martell director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Joseph C Papa director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Renee Gaeta director C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Nathan Caffo officer: Chief Business Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
John J Canepa officer: Chief Financial Officer 241 MATTINSON DRIVE, CONCORD MA 01742